4.7 Letter

Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritiss

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 70, Issue 2, Pages 389-U183

Publisher

B M J PUBLISHING GROUP
DOI: 10.1136/ard.2009.127787

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study

Mariana S. F. Luis, Irene E. M. Bultink, Jose A. P. da Silva, Alexandre E. Voskuyl, Luis S. Ines

Summary: This study identified predictors of renal flares in SLE patients with active proliferative LN, showing that proteinuria levels and age were independent predictors of renal flares in patients who had achieved complete renal response (CRR).

RHEUMATOLOGY (2021)

Article Rheumatology

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome

George C. Drosos, Daisy Vedder, Eline Houben, Laura Boekel, Fabiola Atzeni, Sara Badreh, Dimitrios T. Boumpas, Nina Brodin, Ian N. Bruce, Miguel Angel Gonzalez-Gay, Soren Jacobsen, Gyorgy Kerekes, Francesca Marchiori, Chetan Mukhtyar, Manuel Ramos-Casals, Naveed Sattar, Karen Schreiber, Savino Sciascia, Elisabet Svenungsson, Zoltan Szekanecz, Anne-Kathrin Tausche, Alan Tyndall, Vokko van Halm, Alexandre Voskuyl, Gary J. Macfarlane, Michael M. Ward, Michael T. Nurmohamed, Maria G. Tektonidou

Summary: This study developed recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, emphasizing the importance of regular screening and management of modifiable CVR factors as well as patient education. The recommendations covered CVR prediction tools, interventions on traditional CVR factors, and interventions on disease-related CVR factors.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Review Rheumatology

Treat-to-target in systemic lupus erythematosus: advancing towards its implementation

Agner R. Parra Sanchez, Alexandre E. Voskuyl, Ronald E. van Vollenhoven

Summary: The treat-to-target (T2T) concept, which involves choosing a specific target, evaluating the outcomes, and taking action accordingly, has been successful in improving outcomes for patients with diabetes, hypertension, and rheumatoid arthritis. However, the application of this approach in systemic lupus erythematosus (SLE) requires measurable and achievable outcomes, as well as more therapeutic options. Currently, the available therapeutic options for SLE are limited, and there is a need for more effective and safer treatments. Fortunately, there have been significant advancements in clinical trial activity for SLE, especially with the development of novel therapies. With these expected advancements, it is likely that a wider range of treatments will be available for SLE in the near future, allowing for the routine implementation of a treat-to-target approach.

NATURE REVIEWS RHEUMATOLOGY (2022)

Review Rheumatology

Work participation in patients with systematic lupus erythematosus: a systematic review

Birgit S. Blomjous, Gayle R. S. Gajadin, Alexandre E. Voskuyl, Louise Falzon, Jan L. Hoving, Irene E. M. Bultink, Marieke M. ter Wee

Summary: This systematic review identified variables associated with work participation outcomes in patients with systematic lupus erythematosus (SLE). Factors such as age, ethnicity, educational level, disease activity score, disease duration, disease manifestations, physical functioning, cognitive functioning were found to be predictors for work outcomes. It was also found that certain demographic and disease-related factors were associated with unfavorable work outcomes.

RHEUMATOLOGY (2022)

Article Rheumatology

Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET

Nicki Verweij, Gerben Zwezerijnen, Marieke ter Wee, Jerney de Jongh, Maqsood Yaqub, Dirkjan van Schaardenburg, Adriaan Lammertsma, Alexandre Voskuyl, Willem Lems, Maarten Boers, Conny van der Laken

Summary: This study aimed to investigate the application of macrophage positron emission tomography (PET) in patients with early rheumatoid arthritis (RA). The results showed that macrophage PET assessment after 2 weeks of COBRA light treatment correlated with clinical response after 3 months of treatment.

RMD OPEN (2022)

Editorial Material Rheumatology

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases Comment

Laura Boekel, Femke Hooijberg, Yaelle R. Besten, Erik H. Vogelzang, Maurice Steenhuis, Maureen Leeuw, Sadaf Atiqi, Ronald van Vollenhoven, Willem F. Lems, Wouter H. Bos, Carla A. Wijbrandts, Martijn Gerritsen, Charlotte Krieckaert, Alexandre E. Voskuyl, Irene E. Van der Horst-Bruinsma, Sander W. Tas, Maarten Boers, Theo Rispens, Michael T. Nurmohamed, Gertjan Wolbink

LANCET RHEUMATOLOGY (2022)

Article Medicine, General & Internal

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases

Luuk Wieske, Laura Y. L. Kummer, Koos P. J. van Dam, Eileen W. Stalman, Anneke J. van der Kooi, Joost Raaphorst, Mark Lowenberg, R. Bart Takkenberg, Adriaan G. Volkers, Geert R. A. M. D'Haens, Sander W. Tas, Phyllis Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Joep Killestein, Zoe L. E. van Kempen, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Gertjan Wolbink, Laura Boekel, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Cornelia F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, B. Papay Jallah, Esther Brusse, Pieter A. van Doorn, Adaja E. Baars, Dirkjan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Maurice Steenhuis, Theo Rispens, Anja Ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Filip Eftimov

Summary: This study assessed the occurrence and risk factors for short-term adverse events (AEs) following repeated SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases (IMIDs). The study found that most AEs resolved within 7 days and hospital admissions and allergic reactions were rare.

BMC MEDICINE (2022)

Article Rheumatology

Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis

Nicki J. F. Verweij, Jerney de Jongh, Marieke M. ter Wee, Gerben J. C. Zwezerijnen, Maqsood Yaqub, Alexandre E. Voskuyl, Adriaan A. Lammertsma, Dirkjan Van Schaardenburg, Maarten Boers, Willem F. Lems, Conny J. Van der Laken

Summary: This study investigated the potential of whole-body PET/CT scanning with a macrophage tracer to image arthritis in patients with early RA. The results showed increased uptake of the macrophage PET tracer in the joints of clinically active early RA patients, especially in the feet. Quantitative PET measures showed moderate and significant correlations with clinical outcomes.

JOURNAL OF RHEUMATOLOGY (2022)

Correction Immunology

Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study (vol 2017, 8245879, 2017)

Sylvia J. Kroese, Carolien N. H. Abheiden, Birgit S. Blomjous, Jacob M. van Laar, Ronald W. H. M. Derksen, Irene E. M. Bultink, Alexandre E. Voskuyl, A. Titia Lely, Marjon A. de Boer, Johanna I. P. de Vries, Ruth D. E. Fritsch-Stork

JOURNAL OF IMMUNOLOGY RESEARCH (2022)

Article Rheumatology

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

Laura Boekel, Femke Hooijberg, Erik H. Vogelzang, Yaelle R. Besten, Maureen Leeuw, Sadaf Atiqi, Ronald F. van Vollenhoven, Carla A. Wijbrandts, Martijn Gerritsen, C. Krieckaert, Bas Dijkshoorn, Siham Bakhlakh, Juliette J. Crooijmans, Alexandre Voskuyl, Irene E. van der Horst-bruinsma, Willem Lems, Taco W. Kuijpers, S. Marieke van Ham, Luuk Wieske, Filip Eftimov, Laura Y. Kummer, P. J. Koos van Dam, Eileen W. Stalman, Maurice Steenhuis, Sofie Keijzer, Olvi Cristianawati, Jim Keijser, Floris C. Loeff, Sander W. Tas, Michael T. Nurmohamed, Maarten Boers, Theo Rispens, Gertjan Wolbink

Summary: This study investigated the disease severity of COVID-19 in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) and the development of SARS-CoV-2 antibodies in these patients. The study found that patients with IMIDs, especially those treated with B-cell targeting therapy, were more likely to be hospitalized when infected with SARS-CoV-2. However, treatment with other drugs did not have negative effects on the development of long-lasting humoral immunity against SARS-CoV-2.

RMD OPEN (2022)

Article Rheumatology

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

Luuk Wieske, Koos P. J. van Dam, Maurice Steenhuis, Eileen W. Stalman, Laura Y. L. Kummer, Zoe L. E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, Mark Lowenberg, R. Bart Takkenberg, Geert R. A. M. D'Haens, Phyllis Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederike J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cecile A. C. M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horvath, Jan J. G. M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renee C. F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Papay B. P. Jallah, Esther Brusse, Pieter A. van Doorn, Adaja E. Baars, Dirk Jan Hijnen, Corine R. G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Sofie Keijzer, Jim B. D. Keijser, Arend Boogaard, Olvi Cristianawati, Anja ten Brinke, Niels J. M. Verstegen, Koos A. H. Zwinderman, S. Marieke van Ham, Taco W. Kuijpers, Theo Rispens, Filip Eftimov

Summary: Specific immunosuppressants may impair humoral responses after SARS-CoV-2 vaccination. Most patients receiving immunosuppressant therapy show similar humoral responses to controls after standard vaccination, although antibody titres may be moderately reduced. However, a third vaccination can enhance immune responses in patients with poor humoral responses.

LANCET RHEUMATOLOGY (2022)

Article Rheumatology

Interferon regulatory factor 5 gene variants rs2004640 and rs4728142 are associated with carotid intima media thickness but not with cardiovascular events in rheumatoid arthritis

R. Agca, A. M. van Sijl, S. Vosslamber, A. E. Voskuyl, C. L. Verweij, M. T. Nurmohamed

Summary: IRF5 gene variants rs2004640 and rs4728142 are associated with changes in cIMT, but do not increase the risk of future CV events in patients with RA.

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY (2022)

Article Rheumatology

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

Zgjim Osmani, Thijs J. Schrama, Wendy Zacouris-Verweij, Jeanette Andersen, Susan Frankel, Irene E. M. Bultink, Alain Cornet, Ronald F. van Vollenhoven

Summary: This study assessed HCQ prescription patterns and screening frequencies in European lupus patients, showing that over one-third of patients are prescribed higher than recommended dosages of HCQ, and recent recommendations regarding retinopathy screening are incompletely implemented.

LUPUS SCIENCE & MEDICINE (2021)

No Data Available